Live price temporarily unavailable.
X4 Pharmaceuticals (XFOR) is a Health Care company in the Russell 2000. Latest news and coverage below.
| FY2016Dec 2016 | FY2017Dec 2017 | FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | — | — | $0 | $0 | $3.00M | $0 | $0 | $0 | $2.60M | $35.1M |
| Growth (year over year) | — | — | — | — | — | −100.0% | — | — | — | +1250.5% |
| Gross profit | — | — | — | — | — | — | $0 | $0 | $1.80M | $29.4M |
| Gross margin | — | — | — | — | — | — | — | — | 69.3% | 83.6% |
| Operating income | −$24.3M | −$22.2M | −$29.1M | −$51.7M | −$59.9M | −$85.1M | −$87.6M | −$107.5M | −$36.4M | −$86.9M |
| Operating margin | — | — | — | — | −1995.8% | — | — | — | −1400.0% | −247.4% |
| Net income | −$23.0M | −$22.0M | −$33.3M | −$52.8M | −$62.1M | −$88.7M | −$93.9M | −$101.2M | −$37.5M | −$79.2M |
| Net margin | — | — | — | — | −2071.0% | — | — | — | −1440.4% | −225.6% |
| EPS (diluted) | −$40311.00 | −$49122.00 | −$71235.00 | −$4167.00 | −$92.70 | −$119.70 | −$45.60 | −$17.07 | −$5.59 | −$1.87 |
| Balance sheet | ||||||||||
| Cash and equivalents | $15.2M | $26.7M | $8.13M | $126.2M | $78.7M | $81.8M | $121.7M | $99.2M | $55.7M | $217.0M |
| Total assets | — | $81.3M | $9.94M | $160.7M | $122.9M | $117.2M | $155.6M | $147.3M | $146.4M | $290.5M |
| Total liabilities | — | $22.5M | $21.6M | $31.5M | $50.1M | $52.8M | $81.5M | $96.2M | $124.3M | $104.2M |
| Long-term debt | — | — | $8.31M | $20.0M | $33.2M | $33.1M | $32.3M | $54.6M | $75.0M | $75.0M |
| Shareholders' equity | −$23.1M | −$44.5M | −$77.1M | $129.2M | $72.8M | $64.4M | $74.1M | $51.1M | $22.1M | $186.3M |
| Cash flow | ||||||||||
| Operating cash flow | −$21.6M | −$21.3M | −$25.4M | −$48.1M | −$58.8M | −$70.9M | −$77.1M | −$96.5M | −$130.9M | −$85.6M |
| Capital expenditure | $73.0K | $378.0K | $0 | $174.0K | $1.36M | $615.0K | $103.0K | $60.0K | $326.0K | $0 |
| Free cash flow | −$21.7M | −$21.7M | −$25.4M | −$48.2M | −$60.2M | −$71.5M | −$77.2M | −$96.6M | −$131.2M | −$85.6M |
| Share buybacks | — | — | — | $0 | $0 | $2.00M | $0 | $0 | — | — |
| Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $560.0K | — | $28.8M | $1.97M | $1.76M | — | $2.71M | $8.81M |
| Growth (year over year) | — | — | — | +250.4% | +215.2% | — | −90.6% | +346.3% |
| Gross profit | $333.0K | — | $24.1M | $1.65M | $1.41M | — | $2.11M | $7.19M |
| Gross margin | 59.5% | — | 83.6% | 83.5% | 80.1% | — | 77.9% | 81.6% |
| Operating income | −$34.5M | — | −$9.44M | −$26.2M | −$27.5M | — | −$20.3M | −$16.4M |
| Operating margin | −6160.7% | — | −32.8% | −1329.5% | −1558.6% | — | −749.9% | −186.1% |
| Net income | −$36.7M | — | $282.0K | −$25.7M | −$29.8M | — | −$20.2M | −$16.2M |
| Net margin | −6552.9% | — | 1.0% | −1304.7% | −1689.2% | — | −747.5% | −183.5% |
| EPS (diluted) | −$5.48 | — | $0.04 | −$3.47 | −$0.69 | — | −$0.16 | −$0.13 |
| Balance sheet | ||||||||
| Cash and equivalents | $97.4M | $55.7M | $40.3M | $39.2M | $69.6M | $217.0M | $216.9M | $195.1M |
| Total assets | $178.2M | $146.4M | $130.0M | $105.2M | $163.6M | $290.5M | $270.3M | $253.1M |
| Total liabilities | $118.5M | $124.3M | $107.1M | $101.2M | $101.9M | $104.2M | $101.8M | $97.6M |
| Long-term debt | $75.0M | $75.0M | $75.0M | $75.0M | $75.0M | $75.0M | $75.0M | $75.0M |
| Shareholders' equity | $59.6M | $22.1M | $22.9M | $3.97M | $61.6M | $186.3M | $168.4M | $155.5M |
| Cash flow | ||||||||
| Operating cash flow | −$34.0M | — | −$12.4M | −$29.9M | −$27.8M | — | −$19.6M | −$20.8M |
| Capital expenditure | $92.0K | — | $0 | $0 | $0 | — | — | — |
| Free cash flow | −$34.1M | — | −$12.4M | −$29.9M | −$27.8M | — | — | — |
From X4 Pharmaceuticals's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Filings on SEC EDGAR →
No recent news mentioning X4 Pharmaceuticals in our feed yet.